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The magnitude of underdosage depends on the TSA size (see 
table below). The maximum underdosage (0 cm of solid 
water above flap) generally increases with increasing TSA 
size. However the sensitivity of the TSA to the initial 
reduction of scatter is greatest for the smallest TSA.  
 
 
 
Conclusions: Analysis of the results of this project is still 
ongoing. Considering AAPM recommends a dose calculation 
accuracy of ±2% and a dose delivery accuracy of 5-10% [Nath 
1997] in brachytherapy the underdosage observed is not 
trivial. It is suggested that the underdosage could be 
accounted for during the treatment planning process either 
by increasing the surface dose or by the addition of bolus.  
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Purpose/Objective: Since the past years, the evolution of 
brachytherapy techniques was unique. The main advances 
arise from many features, such as: new dose delivering 
techniques, accuracy in the absorbed dose calculations, 
optimized accessories for implants and patient quality 
assurance, and development of new radioactive sources. The 
Energetic and Nuclear Research Institute (IPEN-CNEN/SP), 
with the main radiotherapy centers in Brazil, created a new 
LDR 192Ir to be used for ocular, prostate and cerebral tumors 
in the low dose rate (LDR) range. The new 192Ir LDR source 
has a cylindrical geometry (3.0 mm and 4.5 mm for outer 
diameter and length, respectively), suitable for accessories 
and holders existent in the market. Since the dosimetric 
characteristics are fundamental for patient dose planning 
accuracy. 
This work evaluate the dosimetric parameters of a new LDR 
brachytherapy 192Ir source using Monte Carlo simulations. 
Materials and Methods: The dosimetric functions were 
obtained using the PENELOPE/penEasy 2008 Monte Carlo 
source code, using the track-length estimator due to the low 
energy of the 192Ir photons. All the dosimetric parameters 
used in this work were based in the American Association 
Physics in Medicine (AAPM) Task Group-43 (TG43). To 
separated simulations runs, with the source in air and liquid 
water phantom, were performed to calculate the air-kerma 
strength (Sk) and water-based dosimetric factors. 
Comparisons of the new 192Ir LDR source dosimetric 
parameters were also made with similar source in the 
market. Uncertainty analysis was computed to estimate the 
statistical variations of the simulated dosimetric data.  
Results: The simulations results provide analogous values 
with LDR brachytherapy sources, for the same energy range. 
The constant dose-rate (L) was 1.11± 0.01 cGy.(hU)-1, 0.5% 
different from a 192Ir LDR source (Best Industries, VA – USA) 
available in the market. Anisotropy functions for the new 192Ir 
LDR sources are slightly steep in few millimeters around the 
source tips, this effect is expected because the encapsulation 
is thicker in these regions than in the wall. Radial dose 
functions were higher around 4.0 cm from the center of 
source (transversal axis), this property shows the possibility 
to use this LDR source for deeper tumors, since the similar 
sources has the maximum radial dose function around 3.0 cm. 
Conclusions: The dosimetric parameters for new 192Ir LDR 
brachytherapy source were calculated using AAPM TG-43. Our 
results suggest that this source has dosimetric characteristics 
comparable with similar LDR commercial sources.  
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Purpose/Objective: Pulmonary seed emboli to the chest may 
occur following permanent prostate brachytherapy (PPB). We 
have reviewed our institutional experience of seed migration 
after PPB comparing loose seeds (LS), mixed loose and 
stranded seeds (MLS), and stranded seeds in an absorbable 
vicryl suture (VS)  
Materials and Methods: Between May 1998 and June 2014, 
1,133 patients underwent PPB at our institution. A total of 
990 consecutive patients with postoperative diagnostic chest 
x-rays were reviewed for analysis of seed migration. Patients 
were grouped based on the type of seed modality implanted: 
LS=397 (40.1%), MS= 46 (4.6%), and VS=547 (55.3%) patients. 
Mick applicator was most frequently used for LS placement. I-
125 and Pd-103 seeds were used in 976 (98.6%) and 14 (1.4%) 
patients, respectively. The mean number of days to chest X-
ray was 109 days (IQR range, 105-149). Pairwise comparison 
was used to determine statistical significance.  
Results: The mean prostate volume and number of seeds 
implanted in each group was 39.9 cc (range, 8-98) and 116 
seeds (range, 49-214), 37.8 cc (range, 17.5-75) and 93.2 
seeds (range, 62-145), and 36.8 cc (range, 13.5-77) and 77.9 
seeds (range, 44-116) for LS, MS, and VS, respectively. The 
overall rate of seed migration was 0.38% (351/93,230). The 
rate of seed migration per group was 0.73% (339/46,346) for 
LS, 0.16% (7/4,288) for MS, and 0.012% (5/42,596) for VS. The 
percent of patients with seed migration and the mean 
number of migrated seeds per patient was 45% and 1.9 seeds 
(range, 1-10) 13% and 1.2 seeds (range, 1-2), and 0.9% and 1 
seed (range, 1), for LS, MS, and VS, respectively. The right 
and left lower lobe were the most frequent sites of 
pulmonary seed migration. Pairwise comparison showed a 
significantly higher rate of seed migration in the LS group 
compared to the MLS (p<0.001) and VS group (p<0.001). 
Patients treated with any number of loose seeds had a 
significantly higher rate of seed migration than patients with 
completely stranded seed implants (p<0.001). 
Conclusions: Our results demonstrate a significantly higher 
rate of seed migration to the chest with use of loose seeds 
compared to stranded seeds. Our results are consistent with 
previous retrospective series and a single prospective study. 
In addition, the present study also provides rates of seed 
migration for mixed loose and stranded implants. Rates of 
seed migration are lowest when 100% of seeds are placed 
using stranded seed material.  
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Purpose/Objective: To investigate the long-term outcome 
for patients treated with high dose-rate brachytherapy (HDR 
BT) in combination with external beam therapy in the years 
2004 to 2005. 5 and 8 year outcome data are presented. 
Materials and Methods: Conformal external beam therapy 
(50 Gy to the pelvis, 40 Gy to the prostate) was delivered in 
combination with two fractions HDR brachytherapy (BT) 
(delta=two weeks) of 15 Gy to the peripheral zone of the 
prostate. A cohort of 80 patients was investigated, treated 
between June 2004 and August 2005 in our clinic. Patient 
mean age was 68.2 years (SD: 5.2). We had 7.5% T1, 62.5% T2 
(17.5% T2a, 27.5% T2b, 17.5% T2c), and 30.0% T3 tumors in 
our study group. 42 of the 80 patients underwent 
antihormonal deprivation therapy. Patient outcome was 
analyzed according the ASTRO criteria. Furthermore PSA 
nadir and PSA bouncing effects were investigated. 
Patients risk groups were evaluated as follows: low: 7.5%, 
intermediate: 35%, high: 57.5%. The long-term results were 
evaluated according to Kaplan-Meier. Statistical significance 
was assumed when p 
Results: The mean follow up time was 68 months. The 5- and 
8-year biochemical (BC) control rates according ASTRO were 
67.7/65.5% for all patients. For the risk groups the following 
8 years BC control rates were found: low risk: 100%, 
intermediate risk: 76.7%, high risk: 56.6%. 
BC control for patients with PSA nadir of  
The mean BC disease free survival (5 years) for patients with 
PSA bouncing was 46% and 85.6% without bouncing 
phenomenon. 
 
 
Conclusions: Data of 80 patients were investigated. The 
results fit well into the already published data of our group. 
With PSA bouncing the results were severely deteriorated .  
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